What the business is, and whether it's a good one at a fair price.
A Chemicals & Petrochemicals company listed on BSE, reporting revenue of ₹0 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Commodity Chemicals peers · as of FY24 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from KOBO BIOTECH LIMITED's filed financials and exchange disclosures
KOBO BIOTECH LIMITED is a Chemicals & Petrochemicals company listed on BSE.
No. Over the trailing twelve months KOBO BIOTECH LIMITED reported a net loss of ₹5 Cr on revenue of ₹0 Cr.
Not in the latest reported year — KOBO BIOTECH LIMITED's dividend payout for FY24 was nil.
Effectively yes. Debt stands at -1.05× equity.
On a typical session KOBO BIOTECH LIMITED moves 3.46% — that is the median absolute close-to-close move across its last 237 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by KOBO BIOTECH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
